[Pj-015] Japanese Poster Session 015「Neuroimmunology: NMOSD and MOGAD 1」

[Pj-015-1] Survey on Use of Inebilizumab for NMOSD (Third interim analysis): Safety and Effectiveness

Kazuo Fujihara^1,2, Yoshito Nagano³, Yoshikazu Naito⁴, Hideaki Hida⁴, Saori Yamauchi⁴, Muneyoshi Kudo⁴, Satoshi Yuki⁴, Shinya Hirota⁴, Kyoko Kato⁴ (1.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Japan, 2.Southern TOHOKU Research Institute for Neuroscience, Japan, 3.Shion Daini Clinic, Japan, 4.Mitsubishi Tanabe Pharma Corporation, Japan)